Real-World Analysis of Outcomes of Venetoclax+Azacitidine Versus 7+3 Induction in Acute Myeloid Leukemia - PubMed
5 days ago
- #acute myeloid leukemia
- #venetoclax
- #real-world evidence
- Study compares Venetoclax+Azacitidine (V+A) vs. 7+3 induction in AML treatment.
- V+A associated with higher 1-year mortality in younger adults (20.6% vs. 8.9%).
- Remission rates favored 7+3 in both younger and older adults.
- Smaller mortality difference in older adults (23.1% vs. 20.5%).
- Findings suggest V+A should be restricted to intensive-ineligible patients.